Atlantic Trust Group LLC raised its stake in shares of Teleflex Incorporated (NYSE:TFX) by 1.8% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 43,397 shares of the medical technology company’s stock after purchasing an additional 762 shares during the period. Atlantic Trust Group LLC owned 0.10% of Teleflex worth $11,065,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in TFX. Princeton Capital Management LLC purchased a new position in shares of Teleflex in the first quarter valued at about $124,000. Aristotle Atlantic Partners LLC purchased a new position in shares of Teleflex in the fourth quarter valued at about $202,000. GWM Advisors LLC purchased a new position in shares of Teleflex in the first quarter valued at about $211,000. Dean Capital Investments Management LLC purchased a new position in shares of Teleflex in the first quarter valued at about $230,000. Finally, IBM Retirement Fund purchased a new position in shares of Teleflex in the first quarter valued at about $253,000. 89.54% of the stock is owned by institutional investors and hedge funds.
NYSE:TFX opened at $281.71 on Friday. The company has a current ratio of 2.18, a quick ratio of 1.45 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $12.63 billion, a P/E ratio of 33.54, a PEG ratio of 1.95 and a beta of 1.19. Teleflex Incorporated has a 12 month low of $197.72 and a 12 month high of $288.78.
The company also recently announced a quarterly dividend, which was paid on Friday, June 15th. Investors of record on Tuesday, May 15th were given a $0.34 dividend. The ex-dividend date of this dividend was Monday, May 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.48%. Teleflex’s dividend payout ratio is currently 16.19%.
Several equities analysts have recently commented on TFX shares. Leerink Swann boosted their price objective on Teleflex from $309.00 to $317.00 and gave the company an “outperform” rating in a research report on Tuesday, June 5th. Goldman Sachs Group started coverage on Teleflex in a research report on Wednesday, April 4th. They issued a “neutral” rating and a $257.00 price objective on the stock. TheStreet downgraded Teleflex from an “a-” rating to a “c+” rating in a research report on Monday, March 12th. Needham & Company LLC restated a “buy” rating and issued a $293.00 price objective (up from $285.00) on shares of Teleflex in a research report on Thursday, May 3rd. Finally, ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $282.50.
In related news, VP John Deren sold 1,347 shares of the business’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $284.57, for a total value of $383,315.79. Following the sale, the vice president now directly owns 1,419 shares in the company, valued at $403,804.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Benson Smith sold 9,331 shares of the business’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $282.34, for a total value of $2,634,514.54. Following the completion of the sale, the director now owns 77,887 shares in the company, valued at $21,990,615.58. The disclosure for this sale can be found here. Insiders sold 57,502 shares of company stock worth $15,281,863 over the last quarter. 2.56% of the stock is owned by company insiders.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.